Loading...
Xxi Lxxs Lxx — Carboplatin Import Profile: Suppliers, Formulations & Sources
Loading...
Pharmaceutical Importer · #6 buyer for Carboplatin · $150.0K import value · 3 shipments · UNITED STATES · DGFT Verified
Xxi Lxxs Lxx is the #6 importer of Carboplatin from India with $150.0K in import value and 3 verified shipments. Xxi Lxxs Lxx holds a 0.2% market share in Carboplatin imports based in UNITED STATES.
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| FRESENIUS KABI ONCOLOGY LIMITED | $27.5M | 735 | 29 |
| INTAS PHARMACEUTICALS LIMITED | $4.9M | 190 | 20 |
| EUGIA PHARMA SPECIALITIES LIMITED | $3.3M | 66 | 3 |
| VENUS REMEDIES LIMITED | $2.7M | 123 | 22 |
| KARDI TRADING PRIVATE LIMITED | $2.6M | 130 | 8 |
| NAPROD LIFE SCIENCES PRIVATE LIMITED | $2.6M | 64 | 11 |
| BETA DRUGS LIMITED | $1.1M | 102 | 16 |
| PLEASANT EXPORTS | $1.1M | 24 | 1 |
| ACCURE LABS PRIVATE LIMITED | $950.0K | 19 | 1 |
| INTAS PHARMACEUTICALS LTD | $950.0K | 19 | 6 |
India's top Carboplatin suppliers include FRESENIUS KABI ONCOLOGY LIMITED, INTAS PHARMACEUTICALS LIMITED, EUGIA PHARMA SPECIALITIES LIMITED. These companies represent the primary source of Carboplatin exports from India, serving buyers like Xxi Lxxs Lxx in UNITED STATES and other global markets.
What Xxi Lxxs Lxx and other importers must comply with to import Carboplatin from India
U.S. Food and Drug Administration (FDA)
Abbreviated New Drug Application (ANDA) for generic drugs, requiring bioequivalence studies and compliance with 21 CFR. Indian manufacturing sites must pass FDA pre-approval inspection.
Typical timeline: 10–18 months for ANDA approval
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA prior to approval
India exported $25.2M worth of Carboplatin through 3,637 shipments from 273 suppliers to 138 countries, serving 829 buyers globally. Xxi Lxxs Lxx imports $150.0K of this total, accounting for 0.2% of India's Carboplatin exports with 3 shipments from UNITED STATES.
Xxi Lxxs Lxx's average Carboplatin order value is $50.0K per consignment, based on 3 shipments totaling $150.0K. Xxi Lxxs Lxx is based in UNITED STATES and ranks #6 among all Carboplatin importers from India by value.
Top Indian Carboplatin suppliers include FRESENIUS KABI ONCOLOGY LIMITED ($27.5M), INTAS PHARMACEUTICALS LIMITED ($4.9M), EUGIA PHARMA SPECIALITIES LIMITED ($3.3M), VENUS REMEDIES LIMITED ($2.7M), KARDI TRADING PRIVATE LIMITED ($2.6M). These companies represent the primary source of Carboplatin exports from India.
Xxi Lxxs Lxx ranks #6 among 829 Carboplatin importers from India with a 0.2% market share. The top 3 importers are FRESENIUS KABI DEUTSCHLAND GMBH ($15.9M), EUGIA US LLC ($1.5M), EUGIA US LLC, ($1.3M). Xxi Lxxs Lxx processed 3 shipments from UNITED STATES.
Latest developments and market context
Detailed market intelligence for Carboplatin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify import regulations and drug registration requirements with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access order-level details, pricing data, supplier connections, and competitive analysis for Xxi Lxxs Lxx's Carboplatin imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Drug Listing with FDA; Import Alert screening; Customs entry via FDA PREDICT system
US-specific labeling per 21 CFR 201 including NDC number, lot, expiry, dosage in English
Note: Subject to FDA Import Alerts and Automatic Detention if facility has open Form 483 observations.
Regulatory information is provided for general reference based on publicly available FDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with FDA or qualified regulatory affairs professionals for case-specific guidance.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 138+ countries, 829+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, supplier contacts, and formulation details for Xxi Lxxs Lxx.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Carboplatin. For current order-level data, contact TransData Nexus.